GlassScriptPhysician profile
Deena Linn
NPI 1487172748
$422.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $85.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $74.72 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.92 | 2021 | |
| Lilly USA, LLC | $46.40 | 2021-2022 | |
| Genzyme Corporation | $43.89 | 2021 | |
| Clovis Oncology, INC. | $22.20 | 2022 | |
| Acrotech Biopharma INC. | $20.56 | 2022 | |
| G1 Therapeutics, INC. | $19.19 | 2022 | |
| Seagen INC. | $19.00 | 2022 | |
| Incyte Corporation | $16.89 | 2022 | |
| Merck Sharp & Dohme LLC | $14.80 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deena Linn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.